International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

详细信息    查看全文

• 作者：Prof Dominique Farge ; MD^a ; ^b ; ^{dominique.farge-bancel@aphp.fr" class="auth_mail" title="E-mail the corresponding author} ; Prof Henri Bounameaux ; MD^c ; Prof Benjamin Brenner ; MD^d ; Francis Cajfinger ; MD^e ; Philippe Debourdeau ; MD^f ; Prof Alok A Khorana ; MD^g ; Prof Ingrid Pabinger ; MD^h ; Susan Solymoss ; MDⁱ ; Prof James Douketis ; MD^j ; Prof Ajay Kakkar ; PhD^k ; ^l
• 刊名：The Lancet Oncology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：17
• 期：10
• 页码：e452-e466
• 全文大小：140 K

文摘

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE and are more likely to have a recurrence of VTE and bleeding while taking anticoagulants. Management of VTE in patients with cancer is a major therapeutic challenge and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME), established to reduce the global burden of VTE in patients with cancer, published international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis. The rapid global adoption of direct oral anticoagulants for management of VTE in patients with cancer is an emerging treatment trend that needs to be addressed based on the current level of evidence. In this Review, we provide an update of the ITAC-CME consensus recommendations based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale. These guidelines aim to address in-hospital and outpatient cancer-associated VTE in specific subgroups of patients with cancer.